Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca’s mRNA-Based AZD8601 Succeeds At Phase II, Propelling Moderna Into Heart Space

Executive Summary

AstraZeneca and Moderna’s mRNA-based candidate AZD8601 has shown promise in a small Phase II heart study, strengthening the latter’s foray into the cardiovascular arena and beyond its vaccine niche.

You may also be interested in...



Nearly Nine Years In The Making, AstraZeneca Finally Unveils New Cambridge R&D Hub

After an expensive and protracted construction, AstraZeneca hopes its Cambridge research center will help foster collaboration and extend its run of R&D success.

SynAct Surveys Its Options As Rheumatoid Arthritis Asset Succeeds At Phase II

The company’s lead candidate, AP1189, has shown promise in a mid-stage rheumatoid arthritis study, sparking plans for an imminent strategic business collaboration. 

NRx’s COVID-19 Vaccine Candidate BriLife Impresses In Phase II

NRx’s BriLife has demonstrated strong potential in early data from a mid-stage COVID-19 trial, spurring the company on to begin a Phase IIb/III study as soon as possible.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel